9 Results for "

CDK9/CycT

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "CDK9/CycT" in MCE Product Catalog:

  • Isoforms Recommended:
  • Targets Recommended:
41
41 Publications Verification
Cat. No.: HY-12214A
CAS No.: 1263373-43-8
Purity:  99.60%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12871B
CAS No.: 2923012-24-0
Purity:  99.75%
Synonyms: BAY-1143572
Target:  

CDK

Research Areas:  

Cancer

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC50 of 13 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12871
CAS No.: 1414943-88-6
Purity:  98.34%
Synonyms: BAY-1143572 Racemate
Target:  

CDK

Research Areas:  

Cancer

Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13231
CAS No.: 1415559-43-1
Purity:  98.52%
Target:  

CDK HIV

Research Areas:  

Infection

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.
loading...
    loading...
Cat. No.: HY-12871C
CAS No.: 2250279-81-1
Purity:  99.38%
Synonyms: BAY-1143572 S-Enantiomer; (+)-Atuveciclib; (+)-BAY-1143572
Target:  

CDK

Research Areas:  

Cancer

Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective CDK9 inhibitor, which inhibits CDK9/CycT1 with an IC50 of 16 nM.
loading...
    loading...
Cat. No.: HY-156795
CAS No.: 3020773-91-2
Target:  

CDK

Research Areas:  

Cancer

PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of CDK9, with the IC50 of 45 nM .
loading...
    loading...
Cat. No.: HY-156083
CAS No.: 3020773-81-0
Target:  

CDK

Research Areas:  

Cancer

PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of CDK9. PROTAC CDK9/CycT1 Degrader-1 can be used as a PROTAC target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors .
loading...
    loading...
Cat. No.: HY-13231R
CAS No.: 1415559-43-1
Target:  

CDK HIV

Research Areas:  

Infection

CDK9-IN-1 (Standard) is the analytical standard of CDK9-IN-1. This product is intended for research and analytical applications. CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.
loading...
    loading...
Cat. No.: HY-P703098
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CCNT1; Cyclin-T1; Prev. HIVE1; Cyclin C-Related Protein; CycT1; MLLT10/CCNT1 Fusion; CCNT; Cyclin-T; Human Immunodeficiency Virus Type 1 (HIV-1) Expression (Elevated) 1; CycT1; Cyclin T1; CDK9-Associated C-Type Protein
Species:  
Source:  
loading...
    loading...